Legend
Please note that a short description of a certain column can be displayed when you move your mouse cursor over the column's header and hold it still. Below, a more detailed description is shown per column.
Effect: The variant's effect on the function of the gene/protein, displayed in the format 'R/C'. R is the value reported by the source (publication, submitter) and this classification may vary between records. C is the value concluded by the curator. Note that in some database the curator uses Summary records to give details on the classification of the variant.Values used: '+' indicating the variant affects function, '+?' probably affects function, '-' does not affect function, '-?' probably does not affect function, '?' effect unknown, '.' effect was not classified.
Exon: number of exon/intron containing variant; 2 = exon 2, 12i = intron 12, 2i_7i = from intron 2 to intron 7, 8i_9 = intron 8/exon 9 boundary, _1 = 5' to exon 1, 18_ = 3' of exon 18, _1_18_ = encompassing the entire 18-exon gene
DNA change (cDNA): description of variant at DNA level, based on a coding DNA reference sequence (following HGVS recommendations); e.g. c.123C>T, c.123_145del, c.123_126dup. For deletions/duplications extending beyond the reference transcript resp. {0}/{2} is used to replace del/dup. Extent of the deletion/duplication should be specified using the genomic description (g.). "-" indicates the variant described on genomic level does not affect the coding DNA reference sequence.
RNA change: description of variant at RNA level (following HGVS recommendations).
- r.123c>u
- r.? = unknown
- r.(?) = RNA not analysed but probably transcribed copy of DNA variant
- r.spl? = RNA not analysed but variant probably affects splicing
- r.(spl?) = RNA not analysed but variant may affect splicing
- r.0? = change expected to abolish transcription
Protein: description of variant at protein level (following HGVS recommendations).
- p.(Arg345Pro) = change predicted from DNA (RNA not analysed)
- p.Arg345Pro = change derived from RNA analysis
- p.? = unknown effect
- p.0? = probably no protein produced
Haplotype: haplotype on which variant was found
Allele: On which allele is the variant located? Does not necessarily imply inheritance! 'Paternal' (confirmed or inferred), 'Maternal' (confirmed or inferred), 'Parent #1' or #2 for compound heterozygosity without having screened the parents, 'Unknown' for heterozygosity without having screened the parents, 'Both' for homozygozity.
Classification method: The method used for the clinical classification of this variant.
All options:
- ACMG
- ACGS
- EAHAD-CFDB
- ENIGMA
- IARC
- InSiGHT
- kConFab
- other
Clinical classification: Clinical classification of variant, preferably based on standardised criteria (e.g. ACMG), directed on the clinical consequences as published/submitted, indicated using an enriched system including inheritance: e.g. pathogenic, pathogenic (dominant), pathogenic (recessive), pathogenic (!), pathogenic (maternal), pathogenic (paternal). Standard inheritance is covered by dominant/recessive, imprinting by maternal/paternal. A '!' warns for exceptional circumstances to be explained in the 'Remarks' field (low penetrance, variants pathogenic in heterozygous state only, hypomorphic/hypermorphic variants, protective variants, etc.). Non-disease consequences (e.g. drug metabolism (pharmacogenetics), risk factor, blood group, tasting bitter) are indicated using additions to the benign classification; benign (dominant), benign (recessive), benign (!), etc. The value 'association' is used for variants associated with a phenotype and 'NA' for variants from in vitro/in silico records. NOTE: classification may differ from the opinion of the curator as given in a variant SUMMARY-record or the 'Functional effect concluded'). NOTE: pathogenic/likely pathogenic should go together with "variant (probably) affects function" In ClassFunctional.
All options:
- pathogenic
- pathogenic (dominant)
- pathogenic (recessive)
- pathogenic (!)
- pathogenic (maternal)
- pathogenic (paternal)
- likely pathogenic
- likely pathogenic (dominant)
- likely pathogenic (recessive)
- likely pathogenic (!)
- likely pathogenic (maternal)
- likely pathogenic (paternal)
- VUS
- VUS (!)
- likely benign
- likely benign (dominant)
- likely benign (recessive)
- likely benign (!)
- likely benign (maternal)
- likely benign (paternal)
- benign
- benign (dominant)
- benign (recessive)
- benign (!)
- benign (maternal)
- benign (paternal)
- conflicting
- association
- NA
DNA change (genomic) (hg19): HGVS description of variant at DNA level, based on the genomic (chromosomal) DNA reference sequence; e.g. g.12345678C>T, g.12345679del, g.12345678_12345890dup
DNA change (hg38): HGVS description of variant at DNA level, based on the hg38 genomic (chromosomal) eference sequence; e.g. g.12345678C>T, g.12345679del, g.12345678_12345890dup
Published as: listed only when different from "DNA change"; variant as reported originally (e.g. 521delT). Variants seen in animal models, tested in vitro, predicted from RNA analysis, etc. are described between brackets like c.(456C>G)
ISCN: description of the variant according to ISCN nomenclature
DB-ID: database ID of variant, grouping multiple observations of the same variant together, starting with the HGNC gene symbol, followed by an underscore (_) and a six digit number (e.g. DMD_012345). _000000 is used for variants where DNA was not analysed (change predicted from RNA analysis), variants seen in animal models or variants not seen in humans but functionally tested in vitro
Variant remarks: remarks regarding variant described, e.g. germline mosaicism in mother, 345 kb deletion, muscle RNA analysed, not in 200 control chromosomes tested, on founder haplotype, etc.
Reference: publication describing the variant submitted, incl. links to OMIM, PubMed or other source, e.g. "den Dunnen ASHG2003 P2346"
ClinVar ID: ID of variant in ClinVar database
dbSNP ID: the dbSNP ID
Origin: Origin of variant/record: Germline = in all cells, De novo = in all cells, but not in either parent, Germline/De novo (untested) = in all cells, parents not tested (use only when De novo is likely, e.g. isolated/sporadic cases with dominant disease), Somatic = present in a subset of cells, but not in either parent, Uniparental disomy = from parental disomy (maternal or paternal), CLASSIFICATION record = submitter only sharing variant classification (note another report may share Individual data), SUMMARY record = master summary record from curator (may link to another database), In vitro (cloned) = data resulting from in vitro functional assays, animal model = data from animal model, Artefact = false positive variant call, DUPLICATE record = variant already described on another chromosome (e.g. unbalanced translocation, duplicating transposition, 2nd fusion transcript, etc.)
All options:
- Germline
- De novo
- Germline/De novo (untested)
- Somatic
- Uniparental disomy
- Uniparental disomy, maternal allele
- Uniparental disomy, paternal allele
- CLASSIFICATION record
- SUMMARY record
- In vitro (cloned)
- In silico
- animal model
- Artefact
- DUPLICATE record
- Unknown
- Not applicable
Segregation: Indicates whether the variant segregates with the phenotype (yes), does not segregate with the phenotype (no) or segregation is unknown (?)
All options:
- ? = unknown
- yes = segregates with phenotype
- no = does not segregate with phenotype
- - = not applicable
Frequency: frequency in which the variant was found; e.g 5/760 chromosomes (in 5 of 760 chromosomes tested), 1/33 patients (in 1 of 33 patients analysed in study), 0.05 controls (in 5% of control cases tested)
Re-site: restriction enzyme recognition site created (+) or destroyed (-); e.g. BglII+;BamHI-
VIP: variant VIP-status was requested for matchmaking - need collaboration(s) to crack the case - please contact the submitter/curator.
NOTE: to get VIP status ask the curator.
Methylation: result of methylation test; GOM (gain of methylation), LOM (loss of methylation), 30% (30% methylated). NOTE: when several tests were done mention the method as well (e.g. MS-PCR 75%)

 Effect
|

 Exon
|

 DNA change (cDNA)
|

 RNA change
|

 Protein
|

 Haplotype
|

 Classification method
|

 Clinical classification
|

 DNA change (genomic) (hg19)
|

 DNA change (hg38)
|

 Published as
|

 ISCN
|

 DB-ID
|
 Variant remarks
|

 Reference
|

 ClinVar ID
|

 dbSNP ID
|

 Origin
|

 Segregation
|

 Frequency
|

 Re-site
|

 VIP
|

 Methylation
|

 Owner
|
?/. |
_1 |
c.-407G>A |
r.= |
p.= |
- |
- |
NA |
g.32889437G>A |
g.32315300G>A |
- |
- |
BRCA2_006627 |
expression cloning luciferase assay no effect |
PubMed: Burke 2018, Journal: Burke 2018 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Lez J Burke |
?/. |
_1 |
c.-395C>T |
r.= |
p.= |
- |
- |
NA |
g.32889449C>T |
g.32315312C>T |
- |
- |
BRCA2_006628 |
expression cloning luciferase assay no effect |
PubMed: Burke 2018, Journal: Burke 2018 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Lez J Burke |
+?/. |
_1 |
c.-296C>T |
r.(=) |
p.(=) |
- |
- |
NA |
g.32889548C>T |
g.32315411C>T |
- |
- |
BRCA2_006630 |
expression cloning luciferase assay 0.5x decreased (MCF7 cells) |
PubMed: Burke 2018, Journal: Burke 2018 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Lez J Burke |
?/. |
_1 |
c.-280del |
r.= |
p.= |
- |
- |
NA |
g.32889564del |
g.32315427del |
- |
- |
BRCA2_006631 |
expression cloning luciferase assay no effect |
PubMed: Burke 2018, Journal: Burke 2018 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Lez J Burke |
?/. |
_1 |
c.-268C>G |
r.= |
p.= |
- |
- |
NA |
g.32889576C>G |
g.32315439C>G |
- |
- |
BRCA2_006633 |
expression cloning luciferase assay no effect |
PubMed: Burke 2018, Journal: Burke 2018 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Lez J Burke |
?/. |
1 |
c.-218G>A |
r.= |
p.= |
- |
- |
NA |
g.32889626G>A |
g.32315489G>A |
- |
- |
BRCA2_006635 |
expression cloning luciferase assay no effect |
PubMed: Burke 2018, Journal: Burke 2018 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Lez J Burke |
?/. |
1 |
c.-200C>T |
r.= |
p.= |
- |
- |
NA |
g.32889644C>T |
g.32315507C>T |
- |
- |
BRCA2_006636 |
expression cloning luciferase assay no effect |
PubMed: Burke 2018, Journal: Burke 2018 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Lez J Burke |
?/. |
1 |
c.-197A>C |
r.= |
p.= |
- |
- |
NA |
g.32889647A>C |
g.32315510A>C |
- |
- |
BRCA2_006637 |
expression cloning luciferase assay no effect |
PubMed: Burke 2018, Journal: Burke 2018 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Lez J Burke |
?/. |
1 |
c.-175C>T |
r.= |
p.= |
- |
- |
NA |
g.32889669C>T |
g.32315532C>T |
- |
- |
BRCA2_003946 |
expression cloning luciferase assay no effect |
PubMed: Burke 2018, Journal: Burke 2018 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Lez J Burke |
?/. |
1 |
c.-133T>G |
r.= |
p.= |
- |
- |
NA |
g.32889711T>G |
g.32315574T>G |
- |
- |
BRCA2_006638 |
expression cloning luciferase assay no effect |
PubMed: Burke 2018, Journal: Burke 2018 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Lez J Burke |
?/. |
1 |
c.-87T>G |
r.= |
p.= |
- |
- |
NA |
g.32889757T>G |
g.32315620T>G |
- |
- |
BRCA2_006639 |
expression cloning luciferase assay no effect |
PubMed: Burke 2018, Journal: Burke 2018 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Lez J Burke |
?/. |
1 |
c.-82G>C |
r.= |
p.= |
- |
- |
NA |
g.32889762G>C |
g.32315625G>C |
- |
- |
BRCA2_005829 |
expression cloning luciferase assay no effect |
PubMed: Burke 2018, Journal: Burke 2018 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Lez J Burke |
+?/. |
1i |
c.-40+1G>A |
r.-138_-40del |
p.(=) |
- |
- |
NA |
g.32889805G>A |
g.32315668G>A |
c.-40+1G>A |
- |
BRCA2_000520 |
Embryonic stem cell assay, RNA analysis; strong functional effect, disruption exon 1 donor site, use of alternative donor site middle of exon 1 (BRCA2 c.-139) |
PubMed: Bakker 2014 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Janine Bakker |
?/. |
1i |
c.-40+8G>A |
r.(?) |
? |
- |
- |
NA |
g.32889812G>A |
g.32315675G>A |
IVS1+8G/A |
- |
BRCA2_000001 |
- |
PubMed: Hadjisavvas 2003 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Peter Devilee |
?/. |
1i |
c.-39-96dup |
r.(?) |
? |
- |
- |
NA |
g.32890463dup |
g.32316326dup |
IVS1-96insA |
- |
BRCA2_000003 |
- |
PubMed: Hadjisavvas 2003 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Peter Devilee |
?/. |
2 |
c.-26G>A |
r.(?) |
? |
- |
- |
NA |
g.32890572G>A |
g.32316435G>A |
203G/A (5' UTR) |
- |
BRCA2_000005 |
- |
PubMed: Diez 2003 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Peter Devilee |
-/. |
2 |
c.-26G>A |
r.(?) |
? |
- |
- |
NA |
g.32890572G>A |
g.32316435G>A |
203G/A (5' UTR) |
- |
BRCA2_000005 |
Prevalence in normal controls; predicted neutral |
PubMed: Wagner 1999 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Peter Devilee |
?/. |
2 |
c.-26G>C |
r.(?) |
? |
- |
- |
NA |
g.32890572G>C |
g.32316435G>C |
203G/C |
- |
BRCA2_000002 |
- |
PubMed: Diez 2003 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Peter Devilee |
-/. |
2 |
c.-14T>G |
r.(?) |
? |
- |
- |
NA |
g.32890584T>G |
g.32316447T>G |
217T/G |
- |
BRCA2_000006 |
Prevalence in normal controls; predicted neutral |
PubMed: Wagner 1999 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Peter Devilee |
?/. |
2 |
c.-11C>T |
r.(?) |
? |
- |
- |
NA |
g.32890587C>T |
g.32316450C>T |
218C>T |
- |
BRCA2_000007 |
- |
PubMed: Diez 2003 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Peter Devilee |
?/. |
2 |
c.51_52del |
r.(?) |
p.Arg18Leufs*12 |
- |
- |
NA |
g.32890648_32890649del |
g.32316511_32316512del |
279delAC |
- |
BRCA2_000008 |
Cell viability (in BRCA-/- cells); as variant control |
PubMed: Kuznetsov 2008 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Peter Devilee |
-/. |
2 |
c.53G>A |
r.(?) |
p.Arg18His |
- |
- |
NA |
g.32890650G>A |
g.32316513G>A |
R18H |
- |
BRCA2_000009 |
Multifactorial likelihood-ratio model; predicted neutral |
PubMed: Spurdle 2008 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Peter Devilee |
?/. |
2i |
c.67+2T>C |
r.(?) |
? |
- |
- |
NA |
g.32890666T>C |
g.32316529T>C |
IVS2+2T/C |
- |
BRCA2_000011 |
- |
PubMed: Diez 2003 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Peter Devilee |
?/. |
2i |
c.67+62T>G |
r.(?) |
? |
- |
- |
NA |
g.32890726T>G |
g.32316589T>G |
IVS2+62T/G |
- |
BRCA2_000012 |
- |
PubMed: Hadjisavvas 2003 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Peter Devilee |
-/. |
2i |
c.67+62T>G |
r.(=) |
? |
- |
- |
NA |
g.32890726T>G |
g.32316589T>G |
IVS2+62T/G |
- |
BRCA2_000012 |
Prevalence in normal controls; predicted neutral |
PubMed: Wagner 1999 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Peter Devilee |
?/. |
2i |
c.68-7del |
r.= |
? |
- |
- |
NA |
g.32893207del |
g.32319070del |
c.68-7delT |
- |
BRCA2_000538 |
splicing reporter minigene/patient RNA analysis; no splicing defect |
PubMed: Théry 2011 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Maaike Vreeswijk |
?/. |
2i |
c.68-7T>A |
r.= |
? |
- |
- |
NA |
g.32893207T>A |
g.32319070T>A |
c.68-7T>A |
- |
BRCA2_000013 |
splicing reporter minigene/patient RNA analysis; no splicing defect |
PubMed: Théry 2011 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Maaike Vreeswijk |
?/. |
2i |
c.68-7T>A |
r.= |
? |
- |
- |
NA |
g.32893207T>A |
g.32319070T>A |
IVS2-7T>A |
- |
BRCA2_000013 |
cDNA analysis; as variant control |
PubMed: Vreeswijk 2008 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Peter Devilee |
+?/. |
3 |
c.73G>A |
r.(?) |
p.Gly25Arg |
- |
- |
NA |
g.32893219G>A |
g.32319082G>A |
- |
- |
BRCA2_000545 |
Embryonic stem cell assay; normal viability, increased sensitivity, reduced HR |
PubMed: Biswas 2012 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Maaike Vreeswijk |
+/. |
3 |
c.79A>G |
r.(?) |
p.Ile27Val |
- |
- |
NA |
g.32893225A>G |
g.32319088A>G |
I27V |
- |
BRCA2_000014 |
Co-localization to predicted ESEs; predicted deleterious |
PubMed: Pettigrew 2007 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Peter Devilee |
+?/. |
3 |
c.91T>C |
r.(?) |
p.Try31Arg |
- |
- |
NA |
g.32893237T>C |
g.32319100T>C |
- |
- |
BRCA2_000546 |
Embryonic stem cell assay; no rescue ES cell lethality |
PubMed: Biswas 2012 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Maaike Vreeswijk |
+?/. |
3 |
c.93G>T |
r.(?) |
p.Try31Cys |
- |
- |
NA |
g.32893239G>T |
g.32319102G>T |
- |
- |
BRCA2_000547 |
Embryonic stem cell assay; no rescue ES cell lethality |
PubMed: Biswas 2012 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Maaike Vreeswijk |
?/. |
3 |
c.125A>G |
r.(?) |
p.Tyr42Cys |
- |
- |
NA |
g.32893271A>G |
g.32319134A>G |
Y42C |
- |
BRCA2_000016 |
- |
PubMed: Bergthorsson 2001 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Peter Devilee |
?/. |
3 |
c.125A>G |
r.(?) |
p.Tyr42Cys |
- |
- |
NA |
g.32893271A>G |
g.32319134A>G |
Y42C |
- |
BRCA2_000016 |
LOH analysis; Loss of wild type allele |
PubMed: Beristain 2010 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Maaike Vreeswijk |
-/. |
3 |
c.125A>G |
r.(?) |
p.Tyr42Cys |
- |
- |
NA |
g.32893271A>G |
g.32319134A>G |
Y42C |
- |
BRCA2_000016 |
Multifactorial likelihood-ratio model; predicted neutral |
PubMed: Chenevix-Trench 2006 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Peter Devilee |
?/. |
3 |
c.125A>G |
r.(?) |
p.Tyr42Cys |
- |
- |
NA |
g.32893271A>G |
g.32319134A>G |
Y42C |
- |
BRCA2_000016 |
- |
PubMed: Edwards 2003 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Peter Devilee |
-/. |
3 |
c.125A>G |
r.(?) |
p.Tyr42Cys |
- |
- |
NA |
g.32893271A>G |
g.32319134A>G |
Y42C |
- |
BRCA2_000016 |
Multifactorial likelihood-ratio model; predicted neutral |
PubMed: Farrugia 2008 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Peter Devilee |
-/. |
3 |
c.125A>G |
r.(?) |
p.Tyr42Cys |
- |
- |
NA |
g.32893271A>G |
g.32319134A>G |
Y42C |
- |
BRCA2_000016 |
Prevalence in normal controls; predicted neutral |
PubMed: Goldgar 2004 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Peter Devilee |
-/. |
3 |
c.125A>G |
r.(?) |
p.Tyr42Cys |
- |
- |
NA |
g.32893271A>G |
g.32319134A>G |
Y42C |
- |
BRCA2_000016 |
Multifactorial likelihood-ratio model; predicted neutral |
PubMed: Goldgar 2004 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Peter Devilee |
-/. |
3 |
c.125A>G |
r.(?) |
p.Tyr42Cys |
- |
- |
NA |
g.32893271A>G |
g.32319134A>G |
Y42C |
- |
BRCA2_000016 |
family history; predicted neutral |
PubMed: Gomez-Garcia 2009 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Peter Devilee |
-/. |
3 |
c.125A>G |
r.(?) |
p.Tyr42Cys |
- |
- |
NA |
g.32893271A>G |
g.32319134A>G |
Y42C |
- |
BRCA2_000016 |
Cell viability (in BRCA-/- cells); as wildtype control |
PubMed: Kuznetsov 2008 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Peter Devilee |
?/. |
3 |
c.125A>G |
r.(?) |
p.Tyr42Cys |
- |
- |
NA |
g.32893271A>G |
g.32319134A>G |
Y42C |
- |
BRCA2_000016 |
Transcription activation in yeast (GAL4-fusions); as variant control |
PubMed: Milner 1997 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Peter Devilee |
?/. |
3 |
c.125A>G |
r.(?) |
p.Tyr42Cys |
- |
- |
NA |
g.32893271A>G |
g.32319134A>G |
Y42C |
- |
BRCA2_000016 |
- |
PubMed: Salazar 2006 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Peter Devilee |
-/. |
3 |
c.125A>G |
r.(?) |
p.Tyr42Cys |
- |
- |
NA |
g.32893271A>G |
g.32319134A>G |
Y42C |
- |
BRCA2_000016 |
Histopathology; predicted neutral |
PubMed: Spearman 2008 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Peter Devilee |
?/. |
3 |
c.125A>G |
r.(?) |
p.Tyr42Cys |
- |
- |
NA |
g.32893271A>G |
g.32319134A>G |
Y42C |
- |
BRCA2_000016 |
- |
PubMed: Spitzer 2000 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Peter Devilee |
?/. |
3 |
c.125A>G |
r.(?) |
p.Tyr42Cys |
- |
- |
NA |
g.32893271A>G |
g.32319134A>G |
Y42C |
- |
BRCA2_000016 |
- |
PubMed: Turner 1999 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Peter Devilee |
+/. |
3 |
c.125A>G |
r.(?) |
p.Tyr42Cys |
- |
- |
NA |
g.32893271A>G |
g.32319134A>G |
Y42C |
- |
BRCA2_000016 |
co-immunoprecipitation BRCA2:RPA; predicted deleterious |
PubMed: Wong 2003 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Peter Devilee |
-/. |
3 |
c.125A>G |
r.(?) |
p.Tyr42Cys |
- |
- |
NA |
g.32893271A>G |
g.32319134A>G |
Y42C |
- |
BRCA2_000016 |
Nuclear localisation; as wildtype control |
PubMed: Wu 2005 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Peter Devilee |
-/. |
3 |
c.125A>G |
r.(?) |
p.Tyr42Cys |
- |
- |
NA |
g.32893271A>G |
g.32319134A>G |
Y42C |
- |
BRCA2_000016 |
co-occurrence with deleterious variant; predicted neutral |
PubMed: Wu 2005 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Peter Devilee |
-/. |
3 |
c.125A>G |
r.(?) |
p.Tyr42Cys |
- |
- |
NA |
g.32893271A>G |
g.32319134A>G |
Y42C |
- |
BRCA2_000016 |
Co-segregation in families; predicted neutral |
PubMed: Wu 2005 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Peter Devilee |
-/. |
3 |
c.125A>G |
r.(?) |
p.Tyr42Cys |
- |
- |
NA |
g.32893271A>G |
g.32319134A>G |
Y42C |
- |
BRCA2_000016 |
Survival assay with VC8 (after MMC treatment); predicted neutral |
PubMed: Wu 2005 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Peter Devilee |
-/. |
3 |
c.125A>G |
r.(?) |
p.Tyr42Cys |
- |
- |
NA |
g.32893271A>G |
g.32319134A>G |
Y42C |
- |
BRCA2_000016 |
Homology-directed repair assay; predicted neutral |
PubMed: Wu 2005 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Peter Devilee |
-/. |
3 |
c.125A>G |
r.(?) |
p.Tyr42Cys |
- |
- |
NA |
g.32893271A>G |
g.32319134A>G |
Y42C |
- |
BRCA2_000016 |
Centrosome amplification; as wildtype control |
PubMed: Wu 2005 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Peter Devilee |
-/. |
3 |
c.125A>G |
r.(?) |
p.Tyr42Cys |
- |
- |
NA |
g.32893271A>G |
g.32319134A>G |
Y42C |
- |
BRCA2_000016 |
evolutionary conservation analysis; predicted neutral |
PubMed: Wu 2005 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Peter Devilee |
+/. |
3 |
c.145G>T |
r.68_316del |
p.[Asp23_Leu105del, Glu49*] |
- |
- |
NA |
g.32893291G>T |
g.32319154G>T |
- |
- |
BRCA2_000017 |
ESEfinder/ESRsearch, hybrid minigenes; ESE disruption, skipping of exon 3 is almost total, but a small fraction of mRNA species with r.145g>u change is present |
PubMed: Sanz 2010 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Eladio A Velasco |
?/. |
3 |
c.145G>T |
r.(?) |
p.Glu49* |
- |
- |
NA |
g.32893291G>T |
g.32319154G>T |
E49X |
- |
BRCA2_000017 |
- |
PubMed: Bergthorsson 2001 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Peter Devilee |
+/. |
3 |
c.156_157insN[?] |
r.(?) |
ND |
- |
- |
NA |
g.32893302_32893303insN[?] |
- |
- |
- |
BRCA2_000518 |
- |
PubMed: Teugels 2009 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Erik Teugels |
-/. |
3 |
c.167A>C |
r.(?) |
p.Asn56Thr |
- |
- |
NA |
g.32893313A>C |
g.32319176A>C |
N56T |
- |
BRCA2_000018 |
Multifactorial likelihood-ratio model; predicted neutral |
PubMed: Easton 2007 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Peter Devilee |
+/. |
3 |
c.189A>C |
r.(?) |
p.Lys63Asn |
- |
- |
NA |
g.32893335A>C |
g.32319198A>C |
K63N |
- |
BRCA2_000019 |
Co-localization to predicted ESEs; predicted deleterious |
PubMed: Pettigrew 2007 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Peter Devilee |
?/. |
3 |
c.223G>C |
r.(?) |
p.Ala75Pro |
- |
- |
NA |
g.32893369G>C |
g.32319232G>C |
A75P |
- |
BRCA2_000020 |
- |
PubMed: Diez 2003 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Peter Devilee |
-/. |
3 |
c.223G>C |
r.(?) |
p.Ala75Pro |
- |
- |
NA |
g.32893369G>C |
g.32319232G>C |
A75P |
- |
BRCA2_000020 |
Multifactorial likelihood-ratio model; predicted neutral |
PubMed: Easton 2007 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Peter Devilee |
?/. |
3 |
c.223G>C |
r.= |
p.Ala75Pro |
- |
- |
NA |
g.32893369G>C |
g.32319232G>C |
c.223G>C |
- |
BRCA2_000020 |
splicing reporter minigene/patient RNA analysis; no splicing defect |
PubMed: Théry 2011 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Maaike Vreeswijk |
?/. |
3 |
c.231T>G |
r.(?) |
p.Thr77Thr |
- |
- |
NA |
g.32893377T>G |
g.32319240T>G |
T77T |
- |
BRCA2_000021 |
- |
PubMed: Hadjisavvas 2003 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Peter Devilee |
+/. |
3i |
c.316+5G>C |
r.spl |
? |
- |
- |
NA |
g.32893467G>C |
g.32319330G>C |
c.316+5G>C |
- |
BRCA2_000015 |
mRNA analysis and splicing reporter minigene; predicted deleterious |
PubMed: Bonnet 2008 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Peter Devilee |
-/. |
3i |
c.317-22C>T |
r.(=) |
? |
- |
- |
NA |
g.32899191C>T |
g.32325054C>T |
IVS3-22C/T |
- |
BRCA2_000023 |
Prevalence in normal controls; predicted neutral |
PubMed: Wagner 1999 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Peter Devilee |
?/. |
4 |
c.322A>C |
r.(?) |
p.Asn108His |
- |
- |
NA |
g.32899218A>C |
g.32325081A>C |
N108H |
- |
BRCA2_000024 |
- |
PubMed: Diez 2003 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Peter Devilee |
-/. |
4 |
c.322A>C |
r.(?) |
p.Asn108His |
- |
- |
NA |
g.32899218A>C |
g.32325081A>C |
N108H |
- |
BRCA2_000024 |
Prevalence in normal controls; predicted neutral |
PubMed: Wagner 1999 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Peter Devilee |
?/. |
4i |
c.425+36A>G |
r.(?) |
? |
- |
- |
NA |
g.32899357A>G |
g.32325220A>G |
IVS4+36A/G |
- |
BRCA2_000025 |
- |
PubMed: Hadjisavvas 2003 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Peter Devilee |
?/. |
4i |
c.426-89T>C |
r.(?) |
? |
- |
- |
NA |
g.32900149T>C |
g.32326012T>C |
IVS4-89T/C |
- |
BRCA2_000028 |
- |
PubMed: Tommasi 2008 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Peter Devilee |
-/. |
4i |
c.426-47G>T |
r.(=) |
? |
- |
- |
NA |
g.32900191G>T |
g.32326054G>T |
IVS4-47G/T |
- |
BRCA2_000026 |
Prevalence in normal controls; predicted neutral |
PubMed: Wagner 1999 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Peter Devilee |
+/. |
4i |
c.426-12_426-8del |
r.spl |
p.(=) |
- |
- |
NA |
g.32900226_32900230del |
g.32326089_32326093del |
IVS4-12del5 |
- |
BRCA2_000022 |
mRNA analysis (RT-PCR); predicted deleterious |
PubMed: Zhang 2009 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Peter Devilee |
+/. |
5 |
c.439C>T |
r.[426_475del, 145g>u] |
p.Pro143Glyfs*22 |
- |
- |
NA |
g.32900251C>T |
g.32326114C>T |
- |
- |
BRCA2_000487 |
ESEfinder/ESRsearch. RT-PCR /hybrid minigenes; ESE disruption/ESS creation, exon 5 skipping |
PubMed: Sanz 2010 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Eladio A Velasco |
-/. |
8 |
c.445A>G |
r.= |
p.Thr225Ala |
- |
- |
NA |
g.32900257A>G |
g.32326120A>G |
T225A |
- |
BRCA2_000042 |
mRNA analysis (RT-PCR); as wildtype control |
PubMed: Sharp 2004 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Peter Devilee |
?/. |
5 |
c.449A>G |
r.(?) |
p.His150Arg |
- |
- |
NA |
g.32900261A>G |
g.32326124A>G |
H150R |
- |
BRCA2_000029 |
- |
PubMed: Salazar 2006 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Peter Devilee |
+/. |
5i |
c.476-2A>G |
r.spl? |
? |
- |
- |
NA |
g.32900377A>G |
g.32326240A>G |
IVS5-2A>G |
- |
BRCA2_000031 |
Multifactorial likelihood-ratio model; predicted deleterious |
PubMed: Easton 2007 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Peter Devilee |
-/. |
6 |
c.502C>A |
r.(?) |
p.Pro168Thr |
- |
- |
NA |
g.32900405C>A |
g.32326268C>A |
P168T |
- |
BRCA2_000033 |
Multifactorial likelihood-ratio model; predicted neutral |
PubMed: Easton 2007 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Peter Devilee |
+/. |
6 |
c.502C>A |
r.(?) |
p.Pro168Thr |
- |
- |
NA |
g.32900405C>A |
g.32326268C>A |
P168T |
- |
BRCA2_000033 |
Co-localization to predicted ESEs; predicted deleterious |
PubMed: Pettigrew 2007 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Peter Devilee |
+/. |
6 |
c.502C>G |
r.(?) |
p.Pro168Ala |
- |
- |
NA |
g.32900405C>G |
g.32326268C>G |
P168A |
- |
BRCA2_000032 |
Co-localization to predicted ESEs; predicted deleterious |
PubMed: Pettigrew 2007 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Peter Devilee |
+/. |
6 |
c.516G>A |
r.[476_516del, 426_516del] |
p.[Val159Glyfs, Ser142Argfs] |
- |
- |
NA |
g.32900419G>A |
g.32326282G>A |
K172K |
- |
BRCA2_000036 |
mRNA analysis; skipping exon 6 and/or both exon 5 and 6 |
PubMed: Hansen 2010 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Maaike Vreeswijk |
+/. |
6 |
c.516G>A |
r.spl |
p.Lys171Lys |
- |
- |
NA |
g.32900419G>A |
g.32326282G>A |
K172K |
- |
BRCA2_000036 |
cDNA analysis; predicted deleterious |
PubMed: Hansen 2009 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Peter Devilee |
?/. |
6i |
c.516+1G>A |
r.= |
? |
- |
- |
NA |
g.32900420G>A |
g.32326283G>A |
IVS6+1G>A |
- |
BRCA2_000035 |
mRNA analysis (RT-PCR); as variant control |
PubMed: Claes 2003 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Peter Devilee |
-/. |
6i |
c.516+14C>T |
r.= |
? |
- |
- |
NA |
g.32900433C>T |
g.32326296C>T |
c.516+14C>T |
- |
BRCA2_000030 |
mRNA analysis and splicing reporter minigene; predicted neutral |
PubMed: Bonnet 2008 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Peter Devilee |
-/. |
6i |
c.516+18T>C |
r.(=) |
? |
- |
- |
NA |
g.32900437T>C |
g.32326300T>C |
IVS6+18T/C |
- |
BRCA2_000034 |
Prevalence in normal controls; predicted neutral |
PubMed: Wagner 1999 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Peter Devilee |
?/. |
6i |
c.517-20A>G |
r.= |
? |
- |
- |
NA |
g.32900616A>G |
g.32326479A>G |
c.517-20A>G |
- |
BRCA2_000539 |
splicing reporter minigene/patient RNA analysis; no splicing defect |
PubMed: Théry 2011 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Maaike Vreeswijk |
-/. |
6i |
c.517-4C>G |
r.spl? |
? |
- |
- |
NA |
g.32900632C>G |
g.32326495C>G |
IVS6-4C>G |
- |
BRCA2_000037 |
Prevalence in normal controls; predicted neutral |
PubMed: Wagner 1999 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Peter Devilee |
+?/. |
7 |
c.517G>T |
r.spl |
p.Gly173Cys |
- |
- |
NA |
g.32900636G>T |
g.32326499G>T |
c.517G>T |
- |
BRCA2_000522 |
splicing reporter minigene; major exon skipping |
PubMed: Gaildrat 2012 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Maaike Vreeswijk |
-?/. |
7 |
c.518G>T |
r.(?) |
p.Gly173Val |
- |
- |
NA |
g.32900637G>T |
g.32326500G>T |
G173V |
- |
BRCA2_000502 |
HR assay, LOH assay; predicted neutral, no LOH |
PubMed: Balia 2011 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Åsa Ehlén |
+?/. |
7 |
c.520C>T |
r.spl |
p.Arg174Cys |
- |
- |
NA |
g.32900639C>T |
g.32326502C>T |
c.520C>T |
- |
BRCA2_000523 |
splicing reporter minigene, patient RNA analysis; major exon skipping |
PubMed: Gaildrat 2012 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Maaike Vreeswijk |
?/. |
7 |
c.522T>G |
r.= |
p.= |
- |
- |
NA |
g.32900641T>G |
g.32326504T>G |
c.522T>G |
- |
BRCA2_000524 |
splicing reporter minigene; no splicing defect |
PubMed: Gaildrat 2012 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Maaike Vreeswijk |
+?/. |
7 |
c.572A>G |
r.spl |
p.Asp191Gly |
- |
- |
NA |
g.32900691A>G |
g.32326554A>G |
c.572A>G |
- |
BRCA2_000525 |
splicing reporter minigene; major exon skipping |
PubMed: Gaildrat 2012 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Maaike Vreeswijk |
+?/. |
7 |
c.572A>T |
r.(?) |
p.Asp191Val |
- |
- |
NA |
g.32900691A>T |
g.32326554A>T |
D191V |
- |
BRCA2_000499 |
HR assay, LOH assay; predicted pathogenic, no LOH |
PubMed: Balia 2011 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Åsa Ehlén |
+?/. |
7 |
c.581G>A |
r.spl |
p.Thp194* |
- |
- |
NA |
g.32900700G>A |
g.32326563G>A |
809G>A |
- |
BRCA2_000517 |
Mouse ES cell assay, RNA analysis, partial exon 7 deletion ; partial rescue lethality; HR as wt |
PubMed: Biswas 2011 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Maaike Vreeswijk |
?/. |
7 |
c.587G>A |
r.spl |
p.Ser196Asn |
- |
- |
NA |
g.32900706G>A |
g.32326569G>A |
c.587G>A |
- |
BRCA2_000526 |
splicing reporter minigene; moderate exon skipping |
PubMed: Gaildrat 2012 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Maaike Vreeswijk |
?/. |
7 |
c.617C>G |
r.[=, 517_631del] |
p.[Ser206Cys, Gly173Serfs] |
- |
- |
NA |
g.32900736C>G |
g.32326599C>G |
c.617C>G |
- |
BRCA2_000527 |
splicing reporter minigene/patient RNA analysis; exon skipping ~50% |
PubMed: Gaildrat 2012 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Maaike Vreeswijk |
+/. |
7 |
c.619A>G |
r.(?) |
p.Thr207Ala |
- |
- |
NA |
g.32900738A>G |
g.32326601A>G |
T207A |
- |
BRCA2_000038 |
Co-localization to predicted ESEs; predicted deleterious |
PubMed: Pettigrew 2007 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Peter Devilee |
?/. |
7 |
c.625C>T |
r.= |
p.Leu209Phe |
- |
- |
NA |
g.32900744C>T |
g.32326607C>T |
c.625C>T |
- |
BRCA2_000528 |
splicing reporter minigene; no splicing defect |
PubMed: Gaildrat 2012 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Maaike Vreeswijk |
+/. |
7 |
c.631G>A |
r.spl |
p.Val211Ile |
- |
- |
NA |
g.32900750G>A |
g.32326613G>A |
V211I |
- |
BRCA2_000040 |
mRNA analysis (RT-PCR); predicted deleterious |
PubMed: Colombo 2009 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Peter Devilee |
+?/. |
7 |
c.631G>A |
r.spl |
p.Val211Ile |
- |
- |
NA |
g.32900750G>A |
g.32326613G>A |
c.631G>A |
- |
BRCA2_000040 |
splicing reporter minigene; major exon skipping |
PubMed: Gaildrat 2012 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Maaike Vreeswijk |
+/. |
7 |
c.631G>A |
r.spl |
p.Val211Ile |
- |
- |
NA |
g.32900750G>A |
g.32326613G>A |
V211I |
- |
BRCA2_000040 |
cDNA analysis; predicted deleterious |
PubMed: Pensabene 2009 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Peter Devilee |
-/. |
7 |
c.631G>A |
r.(?) |
p.Val211Ile |
- |
- |
NA |
g.32900750G>A |
g.32326613G>A |
V211I |
- |
BRCA2_000040 |
Radiation sensitivity; as wildtype control |
PubMed: Pensabene 2009 |
- |
- |
In vitro (cloned) |
- |
- |
- |
- |
- |
Peter Devilee |